Medical - Instruments & Supplies
Compare Stocks
4 / 10Stock Comparison
WRBY vs DBVT vs ALKS vs NVST
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Medical - Equipment & Services
WRBY vs DBVT vs ALKS vs NVST — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology | Biotechnology | Medical - Equipment & Services |
| Market Cap | $3.34B | $1712.35T | $5.90B | $4.04B |
| Revenue (TTM) | $891M | $0.00 | $1.56B | $2.81B |
| Net Income (TTM) | $1M | $-168M | $153M | $68M |
| Gross Margin | 53.4% | — | 65.4% | 55.1% |
| Operating Margin | -0.7% | — | 12.3% | 9.0% |
| Forward P/E | 56.7x | — | 24.8x | 17.2x |
| Total Debt | $233M | $22M | $70M | $1.71B |
| Cash & Equiv. | $286M | $194M | $1.12B | $1.21B |
WRBY vs DBVT vs ALKS vs NVST — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Warby Parker Inc. (WRBY) | 100 | 51.3 | -48.7% |
| DBV Technologies S.… (DBVT) | 100 | 40.8 | -59.2% |
| Alkermes plc (ALKS) | 100 | 114.8 | +14.8% |
| Envista Holdings Co… (NVST) | 100 | 58.1 | -41.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WRBY vs DBVT vs ALKS vs NVST
Each card shows where this stock fits in a portfolio — not just who wins on paper.
WRBY is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 13.0%, EPS growth 107.7%, 3Y rev CAGR 13.4%
- 13.0% revenue growth vs DBVT's -100.0%
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
- +110.4% vs ALKS's +16.5%
ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -11.0% 10Y total return vs NVST's -13.1%
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
- 9.8% margin vs WRBY's 0.2%
NVST is the clearest fit if your priority is value.
- Better valuation composite
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.0% revenue growth vs DBVT's -100.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 9.8% margin vs WRBY's 0.2% | |
| Stability / Safety | Beta 1.06 vs WRBY's 2.22, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +110.4% vs ALKS's +16.5% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
WRBY vs DBVT vs ALKS vs NVST — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
WRBY vs DBVT vs ALKS vs NVST — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 4 of 6 categories
NVST leads 1 • WRBY leads 0 • DBVT leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVST and DBVT operate at a comparable scale, with $2.8B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to WRBY's 0.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $891M | $0 | $1.6B | $2.8B |
| EBITDAEarnings before interest/tax | $32M | -$112M | $212M | $342M |
| Net IncomeAfter-tax profit | $1M | -$168M | $153M | $68M |
| Free Cash FlowCash after capex | $39M | -$151M | $392M | $220M |
| Gross MarginGross profit ÷ Revenue | +53.4% | — | +65.4% | +55.1% |
| Operating MarginEBIT ÷ Revenue | -0.7% | — | +12.3% | +9.0% |
| Net MarginNet income ÷ Revenue | +0.2% | — | +9.8% | +2.4% |
| FCF MarginFCF ÷ Revenue | +4.4% | — | +25.1% | +7.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.3% | — | +28.2% | +14.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +7.5% | +91.5% | -4.1% | +130.0% |
Valuation Metrics
NVST leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ALKS trades at a 99% valuation discount to WRBY's 2076.3x P/E. On an enterprise value basis, NVST's 13.3x EV/EBITDA is more attractive than WRBY's 73.1x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $3.3B | $1712.35T | $5.9B | $4.0B |
| Enterprise ValueMkt cap + debt − cash | $3.3B | $1712.35T | $4.9B | $4.5B |
| Trailing P/EPrice ÷ TTM EPS | 2076.34x | -0.76x | 24.76x | 86.73x |
| Forward P/EPrice ÷ next-FY EPS est. | 56.75x | — | — | 17.21x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 58.08x |
| EV / EBITDAEnterprise value multiple | 73.08x | — | 17.25x | 13.28x |
| Price / SalesMarket cap ÷ Revenue | 3.83x | — | 4.00x | 1.49x |
| Price / BookPrice ÷ Book value/share | 9.25x | 0.66x | 3.28x | 1.32x |
| Price / FCFMarket cap ÷ FCF | 76.32x | — | 12.28x | 17.54x |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to WRBY's 0.63x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +0.4% | -130.2% | +8.8% | +2.2% |
| ROA (TTM)Return on assets | +0.2% | -89.0% | +5.4% | +1.2% |
| ROICReturn on invested capital | -1.3% | — | +18.9% | +4.8% |
| ROCEReturn on capital employed | -1.0% | -145.7% | +14.2% | +4.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.63x | 0.13x | 0.04x | 0.55x |
| Net DebtTotal debt minus cash | -$53M | -$172M | -$1.0B | $496M |
| Cash & Equiv.Liquid assets | $286M | $194M | $1.1B | $1.2B |
| Total DebtShort + long-term debt | $233M | $22M | $70M | $1.7B |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | 32.30x | 12.76x |
Total Returns (Dividends Reinvested)
ALKS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, DBVT leads with a +110.4% total return vs ALKS's +16.5%. The 3-year compound annual growth rate (CAGR) favors WRBY at 31.0% vs NVST's -11.3% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.2% | +4.9% | +25.3% | +12.0% |
| 1-Year ReturnPast 12 months | +68.3% | +110.4% | +16.5% | +44.2% |
| 3-Year ReturnCumulative with dividends | +125.0% | +19.7% | +14.5% | -30.3% |
| 5-Year ReturnCumulative with dividends | -50.1% | -69.1% | +60.9% | -46.6% |
| 10-Year ReturnCumulative with dividends | -50.1% | -87.0% | -11.0% | -13.1% |
| CAGR (3Y)Annualised 3-year return | +31.0% | +6.2% | +4.6% | -11.3% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than WRBY's 2.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.22x | 1.26x | 1.06x | 1.65x |
| 52-Week HighHighest price in past year | $31.00 | $26.18 | $36.60 | $30.42 |
| 52-Week LowLowest price in past year | $14.96 | $7.53 | $25.17 | $16.33 |
| % of 52W HighCurrent price vs 52-week peak | +87.7% | +76.3% | +96.7% | +79.8% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 48.1 | 60.2 | 55.1 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 252K | 2.3M | 2.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: WRBY as "Buy", DBVT as "Buy", ALKS as "Buy", NVST as "Hold". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 7.8% for WRBY (target: $29).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $29.33 | $46.33 | $44.00 | $27.00 |
| # AnalystsCovering analysts | 15 | 15 | 28 | 19 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +4.1% |
ALKS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NVST leads in 1 (Valuation Metrics).
WRBY vs DBVT vs ALKS vs NVST: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WRBY or DBVT or ALKS or NVST a better buy right now?
For growth investors, Warby Parker Inc.
(WRBY) is the stronger pick with 13. 0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Warby Parker Inc. (WRBY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WRBY or DBVT or ALKS or NVST?
On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.
8x versus Warby Parker Inc. at 2076. 3x. On forward P/E, Envista Holdings Corp is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — WRBY or DBVT or ALKS or NVST?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: ALKS returned -11. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WRBY or DBVT or ALKS or NVST?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus Warby Parker Inc. 's 2. 22β — meaning WRBY is approximately 109% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 63% for Warby Parker Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WRBY or DBVT or ALKS or NVST?
By revenue growth (latest reported year), Warby Parker Inc.
(WRBY) is pulling ahead at 13. 0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Warby Parker Inc. grew EPS 107. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, WRBY leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WRBY or DBVT or ALKS or NVST?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -0. 6% for WRBY. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WRBY or DBVT or ALKS or NVST more undervalued right now?
On forward earnings alone, Envista Holdings Corp (NVST) trades at 17.
2x forward P/E versus 56. 7x for Warby Parker Inc. — 39. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — WRBY or DBVT or ALKS or NVST?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is WRBY or DBVT or ALKS or NVST better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
06)). Warby Parker Inc. (WRBY) carries a higher beta of 2. 22 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -11. 0%, WRBY: -50. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WRBY and DBVT and ALKS and NVST?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.